SYN Share Price | Theriva Biologics, Inc. Stock Analysis & Recommendation

Q: What does Theriva Biologics, Inc. do?

Overview: Theriva Biologics, Inc. is a clinical-stage company engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 3.82 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.51 Return on Equity: -114.14% Price to Book: 0.25Contact Details: Address: 9605 Medical Center Dr Ste 270, ROCKVILLE MD: 20850-6382 Tel: 1 734 3327800 Fax: 1 734 3327878 Website: https://www.syntheticbiologics.com/

Q: Is Theriva Biologics, Inc. technically bullish or bearish?

As of 5 June 2025, the technical trend for Theriva Biologics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and bearish signals from the weekly Bollinger Bands. However, there are mildly bullish indicators on the weekly MACD and KST, along with a bullish monthly RSI and OBV. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -76.39% versus the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.28 M

Shareholding (Sep 2025)

FII

0.18%

Held by 5 FIIs

DII

99.36%

Held by 1 DIIs

Promoter

0.00%

How big is Theriva Biologics, Inc.?

22-Jun-2025

As of Jun 18, Theriva Biologics, Inc. has a market capitalization of 3.82 million and reported net sales of 0.00 million with a net profit of -24.82 million over the latest four quarters. Shareholder's funds are at 19.07 million, and total assets are 39.74 million.

View full answer

What does Theriva Biologics, Inc. do?

22-Jun-2025

Theriva Biologics, Inc. is a clinical-stage company focused on developing therapeutics for gastrointestinal diseases, classified as a micro-cap with a market cap of $3.82 million. As of March 2025, it reported a net profit loss of $4 million and has no dividend yield.

View full answer

Who are in the management team of Theriva Biologics, Inc.?

22-Jun-2025

As of March 2022, the management team of Theriva Biologics, Inc. includes Mr. Jeffrey Kraws (Non-Executive Independent Chairman), Mr. Steven Shallcross (CEO, CFO, Director), Dr. John Monahan (Director), and Mr. Jeffrey Wolf (Independent Director).

View full answer

Is Theriva Biologics, Inc. technically bullish or bearish?

20-Sep-2025

As of June 5, 2025, Theriva Biologics, Inc. shows a mildly bearish trend with conflicting indicators, including a bearish daily moving average and weekly Bollinger Bands, but mildly bullish signals from the MACD and KST, while significantly underperforming the S&P 500 with a year-to-date return of -76.39%.

View full answer

Compare Theriva Biologics, Inc. with Similar Stocks

Talphera, Inc.Shuttle Pharmaceuticals Holdings, Inc.Neurosense Therapeutics Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.77

Return on Equity

-249.81%

Price to Book

0.96

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-64.79%

6 Months

-40.7%

1 Year

-52.98%

2 Years

-75.34%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Theriva Biologics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-5.33%

EBIT to Interest (avg)

-17.89

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.51

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.27%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.25

EV to EBIT

0.22

EV to EBITDA

0.22

EV to Capital Employed

-0.53

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-114.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (0.46%)

Foreign Institutions

Held by 5 Foreign Institutions (0.18%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 42.86% vs -133.33% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-5.00",
          "chgp": "12.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.40",
          "val2": "-7.70",
          "chgp": "42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.44% vs 8.50% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.60",
          "val2": "-22.00",
          "chgp": "15.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.60",
          "val2": "0.70",
          "chgp": "-1,185.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.70",
          "val2": "-18.30",
          "chgp": "-40.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.40

-5.00

12.00%

Interest

0.00

Exceptional Items

0.00

-2.90

100.00%

Consolidate Net Profit

-4.40

-7.70

42.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 42.86% vs -133.33% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-18.60

-22.00

15.45%

Interest

0.00

Exceptional Items

-7.60

0.70

-1,185.71%

Consolidate Net Profit

-25.70

-18.30

-40.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.44% vs 8.50% in Dec 2023

All Annual Results

Company CV

About Theriva Biologics, Inc.

Theriva Biologics, Inc.

Pharmaceuticals & Biotechnology

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Company Coordinates

Company Details

9605 Medical Center Dr Ste 270 , ROCKVILLE MD : 20850-6382

Tel: 1 734 3327800

https://www.syntheticbiologics.com/

Registrar Details

Theriva Biologics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Theriva Biologics, Inc.?

Watch in Real-Time

What does Theriva Biologics, Inc. do?

Who are in the management team of Theriva Biologics, Inc.?

Is Theriva Biologics, Inc. technically bullish or bearish?

Compare Theriva Biologics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Theriva Biologics, Inc.

Company Coordinates